Status:
TERMINATED
FAAH Availability in Psychiatric Disorders: A PET Study
Lead Sponsor:
Yale University
Conditions:
Post Traumatic Stress Disorder
Alcohol Use Disorder
Eligibility:
All Genders
18-65 years
Phase:
EARLY_PHASE1
Brief Summary
The aim of the present study is to examine Fatty Acid Amide Hydrolase (FAAH) availability in humans, including healthy individuals and across a spectrum of psychiatric disorders in which alterations i...
Detailed Description
This study involves in vivo examination of FAAH availability, implicated both in the pathophysiology and therapeutics of disorders including PTSD, substance use disorders (e.g., alcohol use disorder, ...
Eligibility Criteria
Inclusion
- Between the ages of 18 and 65 years, inclusive
- Good physical health as determined by history, physical and laboratory examinations, ECG, and vital signs
- PTSD
- Diagnosis of Post-Traumatic Stress Disorder
- AUD
- Diagnosis of Alcohol Use Disorder
- Psychosis
- Diagnosis of psychotic disorder such as Schizophrenia, Schizoaffective disorder
Exclusion
- Presence of ferromagnetic metal in the body or heart pacemaker
- Women with a positive pregnancy test or women who are lactating
Key Trial Info
Start Date :
September 23 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2021
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04404712
Start Date
September 23 2020
End Date
June 30 2021
Last Update
February 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Connecticut Mental Health Center
New Haven, Connecticut, United States, 06519